Liver Center of Texas | Dallas, TX
Status and phase
Conditions
Treatments
About
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
240 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ga Eun Park
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal